Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.14 - $695.9 $13,330 - $66.3 Million
-95,219 Reduced 15.26%
528,673 $74,000
Q3 2022

Nov 14, 2022

BUY
$0.5 - $523.8 $125,481 - $131 Million
250,962 Added 67.29%
623,892 $314,000
Q2 2022

Aug 15, 2022

BUY
$0.63 - $2.58 $234,945 - $962,159
372,930 New
372,930 $324,000
Q1 2022

May 16, 2022

SELL
$1.65 - $3.12 $288,845 - $546,180
-175,058 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$2.31 - $5.85 $404,383 - $1.02 Million
175,058 New
175,058 $452,000
Q4 2019

Feb 14, 2020

SELL
$5.76 - $7.35 $97,073 - $123,869
-16,853 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$6.46 - $8.37 $315,403 - $408,656
-48,824 Reduced 74.34%
16,853 $118,000
Q2 2019

Aug 15, 2019

SELL
$6.34 - $8.8 $7.43 Million - $10.3 Million
-1,172,193 Reduced 94.69%
65,677 $427,000
Q2 2019

Aug 14, 2019

BUY
$6.34 - $8.8 $7.22 Million - $10 Million
1,139,338 Added 1156.31%
1,237,870 $22.7 Million
Q1 2019

May 14, 2019

SELL
$6.06 - $9.0 $1.23 Million - $1.83 Million
-203,161 Reduced 67.34%
98,532 $819,000
Q4 2018

Feb 14, 2019

BUY
$5.18 - $9.35 $642,692 - $1.16 Million
124,072 Added 69.85%
301,693 $1.67 Million
Q3 2018

Nov 14, 2018

BUY
$6.0 - $11.35 $909,456 - $1.72 Million
151,576 Added 581.98%
177,621 $1.57 Million
Q2 2018

Aug 14, 2018

BUY
$4.82 - $8.53 $75,775 - $134,100
15,721 Added 152.28%
26,045 $222,000
Q1 2018

May 15, 2018

BUY
$4.96 - $6.84 $51,207 - $70,616
10,324 New
10,324 $53,000
Q4 2017

Feb 14, 2018

SELL
$4.58 - $10.81 $89,699 - $211,713
-19,585 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$8.25 - $10.81 $161,576 - $211,713
19,585
19,585 $212,000

Others Institutions Holding RDHL

About RedHill Biopharma Ltd.


  • Ticker RDHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 63,823,500
  • Market Cap $507M
  • Description
  • RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...
More about RDHL
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.